Quantcast
The Motley Fool fool.com 02 Aug, 2022 16:30 am

Here's Why Income Investors Should Consider Buying This High-Yield Dividend Stock

Here's Why Income Investors Should Consider Buying This High-Yield Dividend Stock
Novartis is one of the most dominant pharma companies in the world.

8 billion in net sales in the second quarter, which was a 1.Factoring out the unfavorable foreign currency translations that resulted from a strong dollar, Novartis' net sales actually grew 5% during the quarter.What contributed to another quarter of constant currency net sales growth for the company?And nine of those 13 blockbuster products generated low-double-digit to mid-double-digit net sales growth for the company in the quarter.

As has been the case for a while now, the immunology drug Cosentyx and the heart failure drug Entresto led Novartis' net sales higher.Cosentyx's net sales increased 8.

Read full story at fool.com